Authorities in China have approved a drug for the treatment of Alzheimer's disease, the first new medicine with the potential to treat the cognitive disorder in 17 years.
中國有關(guān)部門已批準一種治療阿爾茨海默癥的藥物，這是17年來首個可能對這種認知障礙有治療效果的新藥。

The seaweed-based drug, called Oligomannate, can be used for the treatment of mild to moderate Alzheimer's, according to a statement from China's drug safety agency.
中國藥品安全監(jiān)督管理局發(fā)表的一份聲明顯示，這個被稱為甘露特鈉膠囊的海藻類藥物可以用于治療輕度至中度的阿爾茨海默癥。

The approval is conditional however, meaning that while it can go on sale during additional clinical trials, it will be strictly monitored and could be withdrawn should any safety issues arise.
然而，批準是有條件的，雖然它可以在額外的臨床試驗期間上市銷售，但將受到嚴格監(jiān)督，如果出現(xiàn)任何安全問題，可能會被撤回。

In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer's among people who consume it regularly.
這一新藥的研究團隊由中國科學院上海藥物研究所的耿美玉帶領(lǐng)，他們在九月份說受到啟發(fā)研究海藻是因為經(jīng)常食用海藻的人中阿爾茨海默癥的發(fā)病率相對較低。

In a paper in the journal Cell Research, Geng's team described how a sugar contained within seaweed suppresses certain bacteria contained in the gut which can cause neural degeneration and inflammation of the brain, leading to Alzheimer's.
耿美玉的團隊在《Cell Research》雜志的一篇論文中描述了海藻中的糖如何抑制腸道中某些細菌的，這些細菌會導致神經(jīng)退化和大腦炎癥，從而導致老年癡呆。

This mechanism was confirmed during a clinical trial carried out by Green Valley, a Shanghai-based pharmaceutical company that will be bringing the new drug to market.
這一機制在上海的綠谷制藥公司進行的臨床試驗中得到了證實，該公司將把這種新藥推向市場。

Conducted on 818 patients, the trial found that Oligomannate -- which is derived from brown algae -- can statistically improve cognitive function among people with Alzheimer's in as little as four weeks, according to a statement from Green Valley.
綠谷制藥公司發(fā)布的聲明中說，對818位病人進行的臨床試驗發(fā)現(xiàn)從統(tǒng)計數(shù)據(jù)來看，用褐藻提取物制成的甘露特鈉膠囊在短短四周內(nèi)就能改善老年癡呆人群的認知功能。

"These results advance our understanding of the mechanisms that play a role in Alzheimer's disease and imply that the gut microbiome is a valid target for the development of therapies," neurologist Philip Scheltens, who advises Green Valley and heads the Alzheimer Center Amsterdam, said in the statement.
神經(jīng)學家Philip Scheltens是綠谷制藥公司顧問，也是阿姆斯特丹阿爾茨海默癥中心負責人，他在聲明中說：“這些結(jié)果促進了我們對阿爾茨海默癥發(fā)病機制的理解，并暗示腸道微生物群是治療發(fā)展的有效靶點。”

?

翻譯：菲菲